Mount Yale Investment Advisors LLC Has $1.09 Million Holdings in Cencora, Inc. (NYSE:COR)

Mount Yale Investment Advisors LLC raised its position in Cencora, Inc. (NYSE:COR) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,836 shares of the company’s stock after purchasing an additional 266 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Cencora were worth $1,090,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Financial Advocates Investment Management raised its position in Cencora by 4.7% in the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock valued at $220,000 after buying an additional 44 shares during the last quarter. Checchi Capital Advisers LLC lifted its position in shares of Cencora by 2.2% in the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock worth $499,000 after purchasing an additional 48 shares in the last quarter. Valeo Financial Advisors LLC boosted its holdings in Cencora by 3.4% during the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company’s stock worth $353,000 after purchasing an additional 51 shares during the last quarter. Barlow Wealth Partners Inc. grew its position in Cencora by 5.4% in the second quarter. Barlow Wealth Partners Inc. now owns 1,339 shares of the company’s stock valued at $303,000 after purchasing an additional 68 shares in the last quarter. Finally, Tevis Investment Management increased its stake in Cencora by 4.9% in the 2nd quarter. Tevis Investment Management now owns 1,476 shares of the company’s stock valued at $333,000 after buying an additional 69 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Performance

Shares of COR stock opened at $228.11 on Monday. Cencora, Inc. has a 52 week low of $178.21 and a 52 week high of $247.66. The company has a market capitalization of $45.50 billion, a price-to-earnings ratio of 24.96, a PEG ratio of 1.55 and a beta of 0.44. The company has a 50-day simple moving average of $234.84 and a 200 day simple moving average of $233.10. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. The company had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.92 earnings per share. On average, sell-side analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio is currently 22.32%.

Insider Activity

In related news, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on COR shares. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Bank of America restated a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Robert W. Baird dropped their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Wells Fargo & Company raised their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $256.67.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.